- Home
- RNAZ vs SILO Comparison
RNAZ vs SILO Comparison
Compare RNAZ & SILO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RNAZ
- SILO
- Stock Information
- Founded
- RNAZ 2016
- SILO 2010
- Country
- RNAZ United States
- SILO United States
- Employees
- RNAZ N/A
- SILO N/A
- Industry
- RNAZ Biotechnology: Pharmaceutical Preparations
- SILO Apparel
- Sector
- RNAZ Health Care
- SILO Consumer Discretionary
- Exchange
- RNAZ Nasdaq
- SILO Nasdaq
- Market Cap
- RNAZ 6.1M
- SILO 5.9M
- IPO Year
- RNAZ 2021
- SILO N/A
- Fundamental
- Price
- RNAZ $10.97
- SILO $0.61
- Analyst Decision
- RNAZ Strong Buy
- SILO
- Analyst Count
- RNAZ 1
- SILO 0
- Target Price
- RNAZ $280.00
- SILO N/A
- AVG Volume (30 Days)
- RNAZ 14.3K
- SILO 307.3K
- Earning Date
- RNAZ 08-14-2025
- SILO 08-13-2025
- Dividend Yield
- RNAZ N/A
- SILO N/A
- EPS Growth
- RNAZ N/A
- SILO N/A
- EPS
- RNAZ N/A
- SILO N/A
- Revenue
- RNAZ N/A
- SILO $72,102.00
- Revenue This Year
- RNAZ N/A
- SILO $1.86
- Revenue Next Year
- RNAZ N/A
- SILO N/A
- P/E Ratio
- RNAZ N/A
- SILO N/A
- Revenue Growth
- RNAZ N/A
- SILO N/A
- 52 Week Low
- RNAZ $6.15
- SILO $0.41
- 52 Week High
- RNAZ $739.20
- SILO $3.37
- Technical
- Relative Strength Index (RSI)
- RNAZ 55.77
- SILO 44.10
- Support Level
- RNAZ $9.29
- SILO $0.59
- Resistance Level
- RNAZ $10.48
- SILO $0.67
- Average True Range (ATR)
- RNAZ 0.66
- SILO 0.04
- MACD
- RNAZ 0.02
- SILO -0.01
- Stochastic Oscillator
- RNAZ 100.00
- SILO 14.33
About RNAZ TransCode Therapeutics Inc.
TransCode Therapeutics Inc is a biopharmaceutical company focused on developing and commercializing innovative drugs and diagnostics for treating and identifying cancer. TransCode recently commenced its first clinical trial. The Company's lead therapeutic candidate, TTX-MC138, comprises an oligonucleotide conjugated to an iron oxide nanoparticle designed to be administered by infusion to inhibit the ability of metastatic tumor cells to survive. The goal of the therapy, if approved, is to achieve durable disease regression and long-term patient survival.
About SILO Silo Pharma Inc.
SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's primary program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders.